CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid ... and secured approvals for 16 new drug applications (NDAs) covering 9 indications.

The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.

CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types. Building on promising data from CS5001 monotherapy in later-line aggressive and ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

Upon FDA clearance of the IND application, Tiziana plans to commence a 20-patient clinical trial of two doses of Tiziana’s novel and patented therapeutic candidate, intranasal foralumab ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types. Building on promising data from CS5001 monotherapy in later-line aggressive and ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...